Unknown Manufacturer
Remoxipride is an discontinued atypical antipsychotic selective for dopamine D2 receptors.
Remoxipride is an discontinued atypical antipsychotic selective for dopamine D2 receptors.
Remoxipride is an atypical antipsychotic dopamine D antagonist. Chronic use upregulates the expression of D receptors, while downregulating the expression of D and D receptors in the prefrontal cortex. This activity may be related to the antipsychotic activity of remoxipride. Remoxipride displays weaker binding to D dopaminergic receptors that dopamine. This weaker binding is thought to account for the reduced incidence of Parkinsonism. Remoxipride also increases expression of the protein Fos in the nucleus accumbens but not the dorsolateral striatum, which may be responsible for a reduced incidence of extrapyramidal symptoms.
用于治疗急性和慢性精神分裂症和以妄想、幻觉和思维紊乱为主要症状的其他精神病。
One entry per invention. Patent families filed in the US, EP, WO and CN offices.
No patents found under this name
Patent documents usually refer to a drug by its chemical name or development code rather than its generic name, and applications are only published about 18 months after filing — so a newer drug may not appear here yet.
